Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial.
Administration, Inhalation
Aged
Androstadienes
/ administration & dosage
Benzyl Alcohols
/ administration & dosage
Biomarkers
/ blood
Bronchodilator Agents
/ administration & dosage
C-Reactive Protein
/ analysis
Chlorobenzenes
/ administration & dosage
Drug Therapy, Combination
Feasibility Studies
Female
Fibrinogen
/ analysis
Follow-Up Studies
Forced Expiratory Volume
Humans
Male
Middle Aged
Prognosis
Prospective Studies
Pulmonary Disease, Chronic Obstructive
/ blood
Pulmonary Surfactant-Associated Protein D
/ blood
Receptor for Advanced Glycation End Products
/ blood
Symptom Flare Up
Treatment Outcome
Uteroglobin
/ blood
Lung function decline
biomarkers
chronic obstructive pulmonary disease
mortality
Journal
BMJ open respiratory research
ISSN: 2052-4439
Titre abrégé: BMJ Open Respir Res
Pays: England
ID NLM: 101638061
Informations de publication
Date de publication:
2019
2019
Historique:
received:
20
03
2019
revised:
29
03
2019
entrez:
2
7
2019
pubmed:
2
7
2019
medline:
2
7
2019
Statut:
epublish
Résumé
Systemic levels of C reactive protein (CRP), surfactant protein D (SPD), fibrinogen, soluble receptor of activated glycogen end-product (sRAGE) and club cell protein 16 (CC-16) have been associated with chronic obstructive pulmonary disease (COPD) outcomes. However, they require validation in different cohorts. Relate systemic levels of those proteins to forced expiratory volume in 1 s (FEV Participants were randomised to daily inhalations of placebo, vilanterol 25 µg (VI), fluticasone furoate 100 µg (FF) or their combination (VI 25/FF 100) and followed quarterly until 1000 deaths in the overall 16 485 participants occurred. Biomarker blood samples were available from 1673 patients. The FEV Systemic levels of CC-16, CRP, sRAGE, SPD and fibrinogen did not relate to baseline FEV In COPD, systemic levels of CC-16, CRP, sRAGE, SPD and fibrinogen were not associated with FEV NCT01313676.
Identifiants
pubmed: 31258919
doi: 10.1136/bmjresp-2019-000431
pii: bmjresp-2019-000431
pmc: PMC6561388
doi:
Substances chimiques
AGER protein, human
0
Androstadienes
0
Benzyl Alcohols
0
Biomarkers
0
Bronchodilator Agents
0
Chlorobenzenes
0
Pulmonary Surfactant-Associated Protein D
0
Receptor for Advanced Glycation End Products
0
SCGB1A1 protein, human
0
vilanterol
028LZY775B
Fibrinogen
9001-32-5
C-Reactive Protein
9007-41-4
Uteroglobin
9060-09-7
fluticasone furoate
JS86977WNV
Banques de données
ClinicalTrials.gov
['NCT01313676']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e000431Subventions
Organisme : British Heart Foundation
ID : CH/09/002/26360
Pays : United Kingdom
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Eur Respir J. 2008 Dec;32(6):1451-7
pubmed: 18799503
N Engl J Med. 2011 Sep 29;365(13):1184-92
pubmed: 21991892
Am J Respir Crit Care Med. 2013 Dec 15;188(12):1413-9
pubmed: 24245748
Am J Respir Crit Care Med. 2006 Oct 15;174(8):867-74
pubmed: 16799074
Respir Res. 2017 Oct 24;18(1):180
pubmed: 29065892
Ann Am Thorac Soc. 2017 Dec;14(12):1721-1743
pubmed: 29192815
Expert Opin Ther Targets. 2016 Jul;20(7):869-83
pubmed: 26781659
J Am Coll Cardiol. 2018 Sep 4;72(10):1126-1137
pubmed: 30165984
Chest. 1993 Jan;103(1):196-200
pubmed: 7678080
Am J Respir Crit Care Med. 2012 Dec 15;186(12):1238-47
pubmed: 23144326
Am J Respir Crit Care Med. 2015 Apr 1;191(7):e4-e27
pubmed: 25830527
Inflammation. 2013 Aug;36(4):948-53
pubmed: 23547018
Lancet Respir Med. 2013 Apr;1(2):129-36
pubmed: 24429093
Eur Respir J. 2015 Nov;46(5):1501-3
pubmed: 26160869
Eur Respir J. 2013 May;41(5):1017-22
pubmed: 23018908
PLoS One. 2016 Jul 19;11(7):e0158843
pubmed: 27434033
Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):381-90
pubmed: 10673175
Thorax. 2008 Dec;63(12):1058-63
pubmed: 18757456
Am J Respir Crit Care Med. 2011 May 1;183(9):1129-37
pubmed: 21169466
Am J Respir Crit Care Med. 2016 Mar 15;193(6):607-13
pubmed: 26745765
Proc Am Thorac Soc. 2006 Aug;3(6):465-6
pubmed: 16921105
PLoS One. 2012;7(5):e37483
pubmed: 22624038
Eur Respir J. 2007 Sep;30(3):472-8
pubmed: 17504798
Am J Respir Crit Care Med. 1999 Jan;159(1):179-87
pubmed: 9872837
Am J Respir Crit Care Med. 2007 Feb 1;175(3):250-5
pubmed: 17053205
Respir Res. 2011 Nov 04;12:146
pubmed: 22054035
Am J Respir Crit Care Med. 2013 Oct 15;188(8):948-57
pubmed: 23947473
Eur Respir J. 2009 Jul;34(1):95-102
pubmed: 19164344
J Biomed Biotechnol. 2010;2010:917108
pubmed: 20145712
Thorax. 2006 Jan;61(1):23-8
pubmed: 16143583
Respirology. 2016 Jan;21(1):14-23
pubmed: 26494423
Lancet. 2016 Apr 30;387(10030):1817-26
pubmed: 27203508
Am J Respir Crit Care Med. 2012 May 15;185(10):1065-72
pubmed: 22427534
Am J Respir Crit Care Med. 2004 Oct 1;170(7):760-5
pubmed: 15229100
Am J Respir Crit Care Med. 2006 Jul 1;174(1):6-14
pubmed: 16556692
Am J Respir Crit Care Med. 2001 Sep 15;164(6):1008-11
pubmed: 11587987
Eur Respir J. 2006 May;27(5):902-7
pubmed: 16455829
Curr Drug Targets. 2013 Feb;14(2):177-91
pubmed: 23256717
N Engl J Med. 2012 Oct 4;367(14):1310-20
pubmed: 23034020
Respir Res. 2011 Mar 30;12:37
pubmed: 21450080
Respir Res. 2010 Sep 10;11:122
pubmed: 20831787
JAMA. 2013 Jun 12;309(22):2353-61
pubmed: 23757083
Eur Heart J Acute Cardiovasc Care. 2018 Mar;7(2):129-138
pubmed: 28029055